S Palmeri
Overview
Explore the profile of S Palmeri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Restivo V, Cernigliaro A, Palmeri S, Sinatra I, Costantino C, Casuccio A
J Prev Med Hyg
. 2019 Apr;
59(4 Suppl 2):E26-E30.
PMID: 31016264
Introduction: Socio-economic status (SES) seems to be a determinant of health and is associated with vaccination coverage among older and at-risk populations. The aim of this study was to evaluate...
2.
Scarpitta F, Restivo V, Bono C, Sannasardo C, Vella C, Ventura G, et al.
Ann Ig
. 2019 Apr;
31(2 Supple 1):25-35.
PMID: 30994161
Introduction: The 2017-2019 Italian National Vaccination Plan promotes the improvement of knowledge and attitudes of healthcare workers about vaccine prevention, in order to spread a vaccination culture among general population....
3.
Lapucci C, Gualandi F, Mikulska M, Palmeri S, Mancardi G, Uccelli A, et al.
Mult Scler Relat Disord
. 2018 Sep;
26:52-54.
PMID: 30223229
Background: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). The only report of Serum Sickness (SS) in a MS patient occurred during treatment with natalizumab. Non-protein drugs,...
4.
Palmeri S, Costantino C, DAngelo C, Casuccio N, Ventura G, Vitale F, et al.
Public Health
. 2017 Jun;
150:84-86.
PMID: 28646698
No abstract available.
5.
Malandrini A, DEramo C, Palmeri S, Gaudiano C, Gambelli S, Sicurelli F, et al.
Neurol Sci
. 2012 Jan;
34(1):79-83.
PMID: 22274816
Late-onset Krabbe disease may have variable misleading clinical manifestations and be a puzzling problem for physicians. We report clinical and peripheral nerve studies of three patients with adult-onset Krabbe disease....
6.
Meli M, Palmeri S, Leonardi V, Danova M, Failla G, Russo A, et al.
Oncol Rep
. 2011 May;
1(6):1133-8.
PMID: 21607506
Treatment of advanced head and neck cancer is still a matter of controversy. Although current chemotherapy regimens are able to induce high response rates, they have not shown improved survival....
7.
Meli M, Leonardi V, Palmeri S, Russo A, Rausa L
Oncol Rep
. 2011 May;
3(6):1079-82.
PMID: 21594512
The role of chemotherapy in refractory metastatic breast cancer is still debated. We employed a schedule of cisplatin, mitomycin and vindesine in twenty-one anthracycline- or anthraquinone-pretreated breast cancer patients. The...
8.
Leonardi V, Iannito E, Meli M, Palmeri S
Oncol Rep
. 2011 May;
3(5):919-23.
PMID: 21594482
We enrolled 118 chemonaive cancer patients (pts) to receive OND i.v. dl or GRA i.v. dl. Seventy of the 118 pts received moderately emetogenic (ME) chemotherapy (140 cycles), while 48...
9.
Leonardi V, Meli M, Palmeri S
Oncol Rep
. 2011 May;
4(4):723-7.
PMID: 21590128
We enrolled 11 consecutive pre-treated resistant advanced cancer patients to receive hydroxyurea (HU) (as modulator of MDR) 10 mg/kg/day (d) p.o. d 1-14 in association with DXR (d 15) alone...
10.
Danova M, Mazzini G, Alberici R, Lucotti C, Palmeri S, Fincato G, et al.
Int J Oncol
. 2011 May;
9(5):971-6.
PMID: 21541603
The biological mechanisms by which the association of interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) is expected to effectively reduce the hematological toxicity associated with chemotherapy (CT) are not completely...